Curated News
By: NewsRamp Editorial Staff
June 11, 2025
Telomir's Telomir-1 Shows Promise in Treating Wilson’s Disease
TLDR
- Telomir Pharmaceuticals' Telomir-1 offers a competitive edge in longevity science, showing promise in reversing symptoms of Wilson’s disease and enhancing quality of life.
- Telomir-1 demonstrated a 4- to 5-fold reduction in tremors and 50% lower liver copper levels in zebrafish, indicating its potential mechanism of action.
- Telomir-1's success in preclinical trials represents a hopeful step towards treating Wilson’s disease and improving longevity for humans and animals alike.
- Discover how Telomir-1, a novel drug, significantly improved survival and symptoms in a genetic model of Wilson’s disease, marking a leap in longevity research.
Impact - Why it Matters
This news is significant as it highlights a potential breakthrough in treating Wilson’s disease, a rare and challenging condition, and showcases Telomir Pharmaceuticals' innovative approach to longevity science. The success of Telomir-1 in preclinical trials could pave the way for new treatments that address the root causes of aging and age-related diseases, offering hope for millions affected by these conditions.
Summary
Telomir Pharmaceuticals (NASDAQ: TELO) has unveiled groundbreaking preclinical data demonstrating the efficacy of its lead candidate, Telomir-1, in treating Wilson’s disease, a rare condition characterized by excessive copper accumulation. The study, conducted on zebrafish models, showed Telomir-1's ability to significantly reduce tremors, normalize movement, decrease liver copper levels by half, and improve organ health and survival rates under copper stress. This promising data underscores Telomir-1's potential as a copper-regulating therapeutic, with the company aiming to file an Investigational New Drug (IND) application by the end of the year and commence human trials by 2026. For more details, visit the full press release.
Telomir Pharmaceuticals is at the forefront of longevity science, focusing on the development of Telomir-1, a novel small molecule designed to extend the DNA's telomere caps, which play a critical role in aging and disease. The company's innovative approach aims to combat age-related diseases by addressing telomere shortening, offering hope for improved quality of life and longevity. Discover more about their pioneering work at www.Telodx.com.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Telomir's Telomir-1 Shows Promise in Treating Wilson’s Disease
